The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Eli Lilly and Company is initiating a recall of one specific lot of Trulicity® 0.75MG/0.5ML. The recall extends to lot D396436C.

Product Description	**NDC Number**	**Lot # / Exp Date**
PSI 433004AM, Trulicity® 0.75MG/0.5ML, 4 pens per carton with partition	NDC 0002-1433-80	D396436C / 01-2023

Eli Lilly and Company is recalling a single batch of Trulicity® due to a dose labeling error. As a result of the dose labeling error, a small portion (approximately 2%) of the subject batch of Trulicity® 0.75 mg/ 0.5 ml autoinjector devices contains Trulicity® 1.5 mg/ 0.5 ml autoinjector devices labeled and packaged as 0.75 mg/ 0.5 ml autoinjector devices. Based on medical assessment and the finding that the patient benefit-risk calculus is anticipated to remain positive, this recall is to the retail level.